SURGERY COMBINED WITH INTRA-ARTERIAL CHEMOTHERAPY FOR STAGE IV ADVANCED GASTRIC CANCER

2007 ◽  
Vol 77 (11) ◽  
pp. 1029-1030 ◽  
Author(s):  
Feng Yang ◽  
De liang Fu ◽  
Jiang Long ◽  
Chen Jin ◽  
Xian jun Yu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Stage Iv

Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy

2006 ◽  
Vol 11 (5) ◽  
pp. 367-374 ◽  
Author(s):  
Kohei Shitara ◽  
Atushi Ishiguro ◽  
Masaki Munakata ◽  
Ryouichi Wada ◽  
Yuh Sakata
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Retrospective Analysis ◽  
Stage Iv

scholarly journals A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with SOX

2015 ◽  
Vol 26 ◽  
pp. vii134
Author(s):  
Tatsuo Horie ◽  
Kazuo Mizumoto ◽  
Sigeru Sakano ◽  
Miyako Horie ◽  
Hirokazu Ishibashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Stage Iv ◽  
Her2 Positive ◽  
Unresectable Stage

Chemotherapy with FOLFOX IV in advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14112-14112
Author(s):  
M. A. Garrido. ◽  
G. Melgoza ◽  
H. Galindo ◽  
J. Madrid ◽  
C. Sanchez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Median Overall Survival ◽  
Lung Metastases ◽  
Stage Iv ◽  
Phase Iii ◽  
First Line ◽  
Phase Iii Trial ◽  
Low Toxicity ◽  
Grade 3

14112 Background: Gastric cancer is the first cause of mortality for cancer in Chile. 65% is observed in advanced form and the median survival without surgery is 5,4 months. We hypothesised that chemotherapy and specially FOLFOX IV is an active regimen and has low toxicity in patient with advanced gastric cancer. The main evaluated objectives were: response, toxicity and survival of patient with advanced gastric cancer. Methods: Patients with gastric adenocarcinoma, stage IV that accepted chemotherapy with FOLFOX IV in any time of evolution were included. The evaluation of response was obtained with CT scan every two month. The characteristics of patients, chemotherapy responses, toxicity and global survival were analysed. Results: Between November 2003 and October 2005, 20 patients were included, the median age was 51,5 years (range 28–67), 80% male. Hepatic, peritoneal and lung metastases were the principal places of dissemination. The response rate in first line was: PR 66%, SD 17%, with overall response of 83% (12 patients). In second line the response was: PR 37%, SD 63% (8 patients). The average of treatment was 5,5 months. The median of response was 5 months (2–12). The median overall survival was 12 months. 50% of patients showed toxicity; digestive grade 2 in 2 patients, neurological grade 2 in 4 patients and only 1 patient showed grade 3 toxicity. Conclusions: FOLFOX IV is an active chemotherapy regiment with low toxicity profile in advanced gastric cancer. With these results we propose a Phase III trial would be feasible to perform. No significant financial relationships to disclose.

Postoperative LV5FU2 combination chemotherapy in patients with curative resected advanced gastric cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15660-e15660
Author(s):  
H. Lee ◽  
K. Lee ◽  
E. Park ◽  
I. Hwang ◽  
J. Jang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Continuous Infusion ◽  
Advanced Gastric Cancer ◽  
Cancer Progression ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Postoperative Chemotherapy ◽  
Free Survival ◽  
Grade 3

e15660 Background: To illuminate the effect and toxicity of fortnightly low-dose leucovorin(LV) and fluorouracil(5FU) bolus plus continuous infusion(LV5FU2) postoperative chemotherapy(adjuvant) in patients with curative resected, advanced gastric cancer. Methods: Total 40 patients were enrolled in this study. All patients received LV 20mg/m2(bolus), 5FU 400mg/m2(bolus), 5FU 600mg/m2(24-hour continuous infusion) on day 1, 2, 15, and 16, every 4 weeks(LV5FU2), total 6 cycles. Results: Postoperative chemotherapy was initiated median 19 days after surgery. Total of 238 cycles were administered and median follow-up was 602 days. The median disease-free survival time was 728 days (95% CI, 411∼1045) and 2-year overall survival was 77%. Relapses were reported in 18 (45%) of the patients : Two of 9 patients relapsed in stage IIIA (22.2%), seven of 12 patients relapsed in stage IIIB (58.3%) and nine of 17 patients relapsed in stage IV (52.9%). They were all distant relapsed. Eight patients died. 7 patients died as a result of cancer progression and 1 patient suicided while receiving palliative chemotheraphy for cancer relapse. The grade 3∼4 toxicity of neutropenia 8.4% and anemia 0.4%, neutropenic fever 0.4% were observed. Conclusions: Postoperative LV5FU2 adjuvant chemotherapy is effective and tolerable for the patients with curative resected, advanced gastric cancer. No significant financial relationships to disclose.

A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone

2008 ◽  
Vol 19 (9) ◽  
pp. 921-925 ◽  
Author(s):  
Kenji Ishido ◽  
Wasaburo Koizumi ◽  
Satoshi Tanabe ◽  
Katsuhiko Higuchi ◽  
Tohru Sasaki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Stage Iv ◽  
Term Treatment ◽  
Pathological Response ◽  
Complete Pathological Response ◽  
Short Term ◽  
Short Term Treatment

scholarly journals The Relationship Between ZEB1-AS1 Expression and the Prognosis of Patients With Advanced Gastric Cancer Receiving Chemotherapy

2019 ◽  
Vol 18 ◽  
pp. 153303381984906 ◽  
Author(s):  
Haina Chai ◽  
Chao Sun ◽  
Jun Liu ◽  
Haihui Sheng ◽  
Renyan Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Antisense Rna ◽  
Noncoding Rna ◽  
Stage Iv ◽  
Vital Role ◽  
Clinicopathological Features ◽  
Expression Levels ◽  
Cancer Tissues

Long noncoding RNA ZEB1 antisense RNA 1 plays a vital role in tumorigenesis and metastasis. However, the role of ZEB1 antisense RNA 1 in gastric cancer remains unclear. This study aimed to investigate the expression level of ZEB1 antisense RNA 1 in gastric cancer tissues and evaluate its association with clinicopathological features and prognosis of patients with advanced gastric cancer receiving chemotherapy. The expression levels of ZEB1 antisense RNA 1 were examined in 224 pairs of gastric cancer and adjacent noncancerous tissues by quantitative real-time polymerase chain reaction. The associations between ZEB1 antisense RNA 1 expression and clinicopathological features or survival of patients with advanced gastric cancer were assessed. The results showed that the expression levels of ZEB1 antisense RNA 1 in gastric cancer tissues were significantly higher than those in the paracancerous tissues ( P < .001). Moreover, the high ZEB1 antisense RNA 1 expression was associated with tumor, nodes, and metastases stage IV ( P = .018) and loss of E-cadherin expression ( P = .033). Multivariate Cox hazards regression analysis revealed that high ZEB1 antisense RNA 1 expression was an independent risk factor for predicting poor prognosis in patients with advanced gastric cancer (hazard ratio = 1.530, 95% confidence interval, 1.052-2.224, P = .026). In conclusion, the present findings suggest that ZEB1 antisense RNA 1 is an independent prognostic factor for patients with advanced gastric cancer receiving chemotherapy.

scholarly journals Conversion Surgery for Patients With Stage IV HER2-Positive Gastric Cancer: A Report of 3 Patients

2017 ◽  
Vol 102 (3-4) ◽  
pp. 137-140 ◽  
Author(s):  
Shin Saito ◽  
Yoshinori Hosoya ◽  
Hirofumi Fujii ◽  
Hideyuki Ohzawa ◽  
Akira Tanaka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Targeted Therapy ◽  
Advanced Gastric Cancer ◽  
Molecular Targeted Therapy ◽  
Stage Iv ◽  
Complete Response ◽  
Conversion Surgery ◽  
Her2 Positive ◽  
Stage Iv Gastric Cancer ◽  
Metastatic Lesions

Gastric cancer is a common malignancy and remains potentially lethal. The prognosis of patients with stage IV gastric cancer is thought to be poor, but new molecular targeted therapy may benefit patients with advanced gastric cancer. Currently, conversion surgery after chemotherapy with a trastuzumab-containing regimen is reported to be effective in these patients. We present 3 patients with human epidermal growth factor receptor 2 (HER2)–positive advanced gastric cancer who underwent conversion surgery after receiving a trastuzumab-containing chemotherapy regimen. Interestingly, the primary lesion acquired resistance to the trastuzumab-containing regimen, although the metastatic lesions maintained a complete response. The reason why the primary lesions became resistant to trastuzumab remains unclear. More studies are needed to clarify the mechanism of resistance. Conversion surgery, made possible by the use of molecular-targeted therapy, may improve the prognosis of patients with stage IV gastric cancer, particularly if metastatic lesions show a complete response to therapy.

The impact of the extent of gastric resection on advanced gastric cancer treated with systemic chemotherapy.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 194-194
Author(s):  
Yusuke Sasaki ◽  
Yutaka Watanabe ◽  
Ichiro Ohkita ◽  
Jojo Hirota ◽  
Jun Konno
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Systemic Chemotherapy ◽  
Gastric Resection ◽  
Stage Iv ◽  
Patient Characteristics ◽  
Severe Toxicity ◽  
Stage Iv Gastric Cancer ◽  
Significant Difference ◽  
The Impact

194 Background: In previous clinical trials of adjuvant chemotherapy for gastric cancer, severe toxicity and discontinuation of chemotherapy was more common in patients receiving total gastrectomy (TG) than in those with distal gastrectomy (DG). However, data on the significance of the extent of gastric resection for stage IV gastric cancer treated with systemic chemotherapy are not available. Methods: This is a retrospective review of patients who were received chemotherapy with S-1 and cisplatin for stage IV gastric cancer at our institution between June 2009 and August 2015. The patients were classified into three groups according to the extent of gastrectomy (TG, DG and no gastric resection (NG)) before chemotherapy. Patient characteristics, survival and toxicities of chemotherapy were compared between three groups. Results: Among the 83 patients, 24 underwent TG, 19 DG, and 40 NG. Patient characteristics were well balanced between three groups. There was no significant difference in the requirement for dose reduction between TG, DG and NG patients (29% vs 11% vs 20%, respectively, p= 0.32). However, the rate of discontinuation because of toxicity was significantly higher in TG than in DG or NG patients (46% vs 16% vs 25%, respectively, p= 0.04). The main reasons of discontinuation were anorexia (43%), myelosuppression (23%), nausea (18%) and diarrhea (16%). The median progression-free survival was 8.9, 6.1 and 5.3 months ( p= 0.25), and the median overall survival was 16.0, 16.0 and 9.8 months ( p= 0.40) in the patients with TG, DG and NG, respectively. Conclusions: There was a high frequency of discontinuation of systemic chemotherapy in the advanced gastric cancer patients who underwent TG, but it was not associated with prognosis.

Sign in / Sign up

Export Citation Format

Share Document